top of page

Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New...

“The addition of these new targets will build on the productive multi-year collaboration between Precision and Servier that is driving the development of PBCAR0191, our lead allogeneic CAR T candidate targeting CD19."

091720 - Precision BioSciences and Servi
Download • 86KB

bottom of page